MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
2025 · Blood · 7 citations
https://doi.org/10.1182/blood.2024026685
A
Anke Schilhabel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
39
Papers
667
Citations
13
h-index
14
i10-index
Anke Schilhabel is an academic researcher from Hochschule für Angewandte Wissenschaften Kiel. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 13, co-authored 34 publications.
Papers by this author
worksThe gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category
2024 · Leukemia · 5 citations
https://doi.org/10.1038/s41375-024-02265-z
Comparative Analysis of Four NGS Protocols for Measurable Residual Disease Assessment Testing ctDNA and Bone Marrow Samples in Multiple Myeloma
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)03426-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat